Overview

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.
Phase:
Phase 3
Details
Lead Sponsor:
Somerset Pharmaceuticals
Treatments:
Selegiline